Tigen is a Swiss clinical stage biotech company developing cell therapies to cure cancer. A disruptive catalyst, combining a unique culture with a multidisciplinary set of world-class capabilities and a long-term perspective to accelerate access to novel T-cell therapies for patients and society.
- Emmanuel Savioz, CEO; Benjamin Gilgen, Marketing & Communications
We are a good place to work, diverse and inclusive. Our aim is to accelerate the access to breakthrough cancer therapies.
We are one team, yet multidisciplinary and with a long-term perspective.
The creative and fearless scientists on the quest to explore new ideas. The believers and doers that challenge the status quo to advance and democratise cell & gene therapies.
Switzerland has everything to be a leading hub for cell & gene therapies. Let's all work together to stay at the forefront and shape the next generation of cell & gene therapies.
The whole cell & gene ecosystem will have to transform and gain speed to stay relevant in a global movement towards precision medicine. That includes stakeholders like scientists, clinicians, engineers, academia, patients, authorities, regulators, policy makers, pharma cos, payors or investors.